“…The ethical, social and legal issues concerning pharmacogenomics presented in table 1 are familiar to experienced researchers and institutional review boards, because these issues do not differ from those relevant to genetic testing or screening in general as reported in the wider literature on genetics [60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87]. Nevertheless, these issues will probably become even more complex with the entry of drugs based on pharmacogenomics into the public sphere.…”